By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Miscellaneous antineoplastics > Krazati > Krazati Dosage
Miscellaneous antineoplastics
https://themeditary.com/dosage-information/krazati-dosage-15649.html

Krazati Dosage

Drug Detail:Krazati (Adagrasib)

Generic Name: ADAGRASIB 200mg

Dosage Form: tablet, coated

Drug Class: Miscellaneous antineoplastics

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Patient Selection

Select patients for treatment of locally advanced or metastatic NSCLC with KRAZATI based on the presence of KRAS G12C mutation in plasma or tumor specimens [see Clinical Studies (14)]. If no mutation is detected in a plasma specimen, test tumor tissue.

Information on FDA-approved tests for the detection of a KRAS G12C mutation is available at: https://www.fda.gov/CompanionDiagnostics

Recommended Dosage

The recommended dosage of KRAZATI is 600 mg orally twice daily until disease progression or unacceptable toxicity.

Take KRAZATI at the same time every day with or without food [see Clinical Pharmacology (12.3)]. Swallow tablets whole. Do not chew, crush or split tablets.

If vomiting occurs after taking KRAZATI, do not take an additional dose. Resume dosing at the next scheduled time.

If a dose is inadvertently missed, it should be skipped if greater than 4 hours have elapsed from the expected dosing time. Resume dosing at the next scheduled time.

Dosage Modifications for Adverse Reactions

Recommended dose reductions for adverse reactions are outlined in Table 1. If adverse reactions occur, a maximum of two dose reductions are permitted. Permanently discontinue KRAZATI in patients who are unable to tolerate 600 mg once daily.

Table 1: Recommended KRAZATI Dosage Reductions for Adverse Reactions
Dose Reduction Dosage
First dose reduction 400 mg twice daily
Second dose reduction 600 mg once daily

The recommended dosage modifications for adverse reactions are provided in Table 2.

Table 2: Recommended KRAZATI Dosage Modifications for Adverse Reactions
Adverse reaction Severity* Dosage Modification
ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal
*
Grading defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0
Nausea or vomiting despite appropriate supportive care
(including anti-emetic therapy)
[see Warnings and Precautions (5.1)]
Grade 3 or 4
  • Withhold KRAZATI until recovery to ≤ Grade 1 or return to baseline.
  • Resume KRAZATI at the next lower dose level.
Diarrhea despite appropriate supportive care (including anti-diarrheal therapy)
[see Warnings and Precautions (5.1)]
Grade 3 or 4
  • Withhold KRAZATI until recovery to ≤ Grade 1 or return to baseline.
  • Resume KRAZATI at the next lower dose level.
QTc Interval Prolongation
[see Warnings and Precautions (5.2)]
QTc absolute value greater than 500 ms
or
Greater than an increase of 60 ms from baseline
  • Withhold KRAZATI until QTc interval less than 481 ms or return to baseline.
  • Resume KRAZATI at the next lower dose level.
Torsade de pointes, polymorphic ventricular tachycardia or signs or symptoms of serious or life-threatening arrhythmia
  • Permanently discontinue KRAZATI.
Hepatotoxicity
[see Warnings and Precautions (5.3)]
Grade 2
AST or ALT
  • Decrease KRAZATI to the next lower dose level.
Grade 3 or 4
AST or ALT
  • Withhold KRAZATI until recovery to ≤ Grade 1 or return to baseline.
  • Resume KRAZATI at the next lower dose level.
AST or ALT > 3 × ULN with total bilirubin > 2 × ULN in the absence of alternative causes
  • Permanently discontinue KRAZATI.
Interstitial Lung Disease / Pneumonitis
[see Warnings and Precautions (5.4)]
Any Grade
  • Withhold KRAZATI if ILD/pneumonitis is suspected.
  • Permanently discontinue KRAZATI if ILD/pneumonitis is confirmed.
Other Adverse Reactions
[see Adverse Reactions (6.1)]
Grade 3 or 4
  • Withhold KRAZATI until ≤ Grade 1 or return to baseline.
  • Resume KRAZATI at the next lower dose level.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by